Clinical Course Detection and Prevention of Ovarian Epithelial Tumors

Slide 1 · Clinical Course, Detection,and Prevention of OvarianEpithelial Tumors

Ovarian epithelial neoplasms • Clinicopathologic interpretation

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning objectives

Distinguish benign, borderline, and malignant ovarian epithelial tumor courses.

Connect local mass effects, peritoneal dissemination, and constitutional symptoms with underlying disease.

Explain why early detection remains difficult and how CA-125 should be interpreted.

Relate hereditary predisposition and tubal origins to risk-reducing interventions.

Slide 3 · The central clinical problem

Ovarian carcinomas commonly produce overlapping, nonspecific complaints.

Carcinomas often present after extension beyond the ovary or tube.

The burden of extraovarian disease strongly influences clinical outcome.

Symptoms are shared

Spread changes prognosis

Detection is difficult

Slide 4 · Biologic categories predict different courses

Benign

Well-differentiated epithelial proliferation; Usually cured by resection.

Borderline

Increased epithelial proliferation without destructive stromal invasion.

Malignant

Stromal invasion; May disseminate along peritoneal surfaces and beyond.

Slide 5 · Histologic type is distinct from biologic behavior

Differentiation

Serous, mucinous, and endometrioid are the major epithelial phenotypes.

Behavior

Benign, borderline, and malignant describe invasive potential and clinical course.

Slide 6 · Most ovarian tumors are benign

Approximately 80% of all ovarian tumors are benign overview.

Benign neoplasms predominate in younger patients.

Malignant epithelial tumors occur more often in older patients; High-grade serous tumors account for many carcinomas.

Tumor frequency ≠ cancer frequency

Age influences case mix

Slide 7 · Some tumors remain undetected until large

Early lesion

Increasing mass

Organ compression

Symptoms / discovery

Benign lesions can be incidental and asymptomatic.

Nonfunctional tumors frequently cause symptoms only after reaching substantial size.

Schematic

Slide 8 · Type I and type II: Distinct trajectories

Type I group

Often associated with borderline tumors or endometriosis; Typically lower-grade progression.

Type II group

High-grade serous carcinoma commonly arises from the distal fallopian tube and presents aggressively.

Slide 9 · A tubal precursor explains apparently ovarian disease

Tubal fimbria

STIC

Exfoliated cells

Peritoneal deposits

Serous tubal intraepithelial carcinoma (STIC) is a recognized precursor associated with many high-grade serous carcinomas.

Tubal carcinoma cells may exfoliate and implant on ovarian or peritoneal surfaces.

Schematic

Slide 10 · High-grade serous carcinoma: Anatomic origin matters

The source considers most high-grade serous carcinomas likely to begin in fallopian tube epithelium.

A primary ovarian mass does not necessarily indicate that transformation began in ovarian surface cells.

The tubal-origin model informs the rationale for risk-reducing salpingectomy.

Tumor site ≠ origin site

Prevention target: Tube

Slide 11 · Serous tumors: Grade shapes prognosis

Low-grade serous carcinoma

May arise with serous borderline lesions; Relatively indolent even after extraovarian extension.

High-grade serous carcinoma

Often widely metastatic within the abdomen at diagnosis; Typically rapid clinical deterioration.

Slide 12 · Borderline serous disease can involve the peritoneum

Primary borderline tumor

Noninvasive implant

Long interval

Possible complication

Serous borderline tumors may have noninvasive peritoneal implants.

Indolent implants can remain asymptomatic for extended periods; Progressive disease can eventually cause obstruction.

Schematic

Slide 13 · Peritoneal spread need not imply rapid progression

Borderline / low grade

May persist or recur for many years after dissemination.

High grade

May involve extensive abdominal surfaces at first presentation and worsen quickly.

Slide 14 · Mucinous tumors: Primary cancer is uncommon

The majority of ovarian mucinous tumors are benign or borderline.

Primary ovarian mucinous carcinoma is an uncommon ovarian cancer subtype.

Mucinous epithelial tumors may form very large multiloculated cystic masses.

Mass effect can dominate

Malignancy must be assessed separately

Slide 15 · Bilateral ovarian mucinous masses require caution

Primary ovarian mucinous tumor

Typically unilateral description.

Bilateral mucinous involvement

Requires exclusion of metastatic disease from a nonovarian primary.

Slide 16 · Pseudomyxoma peritonei: Avoid mistaken attribution

Appendiceal source

Peritoneal mucin / implants

Adhesions

Intestinal obstruction

Mucinous ascites and peritoneal epithelial implants can cause adhesions and bowel obstruction.

The appendix, rather than the ovary, as the usual primary site.

Schematic

Slide 17 · Endometrioid ovarian carcinoma: Linked clinical context

Endometriosis coexists with a subset of ovarian endometrioid carcinomas.

Concomitant endometrial and ovarian carcinoma demands evaluation of a possible uterine primary with ovarian metastasis.

Ovarian endometrioid tumors can be bilateral when disease extends beyond the genital tract.

Endometriosis association

Primary-site distinction

Slide 18 · Ovarian clear cell carcinoma: Stage is critical

Disease confined to ovary

The source reports a favorable outcome relative to advanced disease.

Advanced-stage disease

Clear-cell histology is associated with a poor outcome once disease is advanced.

Slide 19 · Brenner tumors: An important clinical contrast

Benign Brenner tumor

Usually an incidental lesion with benign behavior, even when large.

Malignant transitional phenotype

Uncommon lesions have a course that differs by grade and may resemble other ovarian carcinomas.

Slide 20 · Lower abdominal pain is a frequent presentation

Lower abdominal pain is a common manifestation across ovarian carcinoma subtypes.

Pain alone does not identify serous, mucinous, or endometrioid histology.

Interpret the symptom in the context of pelvic mass, distribution of disease, and associated complaints.

Frequent

Nonspecific

Anatomy-dependent

Slide 21 · Abdominal enlargement has more than one cause

Growing adnexal mass

Large ovarian tumors can increase abdominal girth by their own bulk.

Peritoneal disease with ascites

Capsular extension and peritoneal implants may generate substantial ascitic fluid.

Slide 22 · Gastrointestinal complaints are part of the presentation

Ovarian tumors may produce gastrointestinal complaints before their origin is clinically obvious.

Local mass effect and peritoneal disease can contribute to bowel symptoms.

Advanced or indolent peritoneal disease can eventually lead to intestinal obstruction.

Mass effect

Serosal involvement

Obstructive complications

Slide 23 · Urinary symptoms may arise from pelvic involvement

Urinary frequency and dysuria occur among the reported symptoms.

Pelvic pressure can accompany urinary or gastrointestinal complaints.

Symptom location reflects anatomy but does not establish a specific tumor subtype.

Frequency

Dysuria

Pelvic pressure

Slide 24 · Clinical manifestations overlap across subtypes

Local

Lower abdominal pain; Pelvic pressure.

Compression

Urinary frequency, dysuria, and gastrointestinal complaints.

Systemic / advanced

Weakness, weight loss, cachexia; Ascites after peritoneal spread.

Slide 25 · Benign lesions usually follow a favorable course

Benign lesion

Detection

Resection

Cure

Benign ovarian epithelial lesions can be found incidentally or because they become large.

Surgical resection is generally curative according to the source.

Schematic

Slide 26 · Malignancy may produce constitutional decline

Progressive weakness, weight loss, and cachexia are described in ovarian malignancy.

These systemic features contrast with the predominantly local or incidental course of many benign lesions.

Constitutional deterioration often accompanies established tumor burden.

Weakness

Weight loss

Cachexia

Slide 27 · Capsular extension precedes peritoneal seeding

Local invasive tumor

Capsular / surface access

Exfoliated tumor cells

Peritoneal deposits

Carcinoma extends through the tumor capsule or reaches the peritoneal surface.

Exfoliated malignant cells can seed the peritoneal cavity.

Schematic

Slide 28 · Exfoliation provides a route of abdominal dissemination

Primary lesion

Cell shedding

Transport in cavity

Serosal implantation

Tumor cells may detach into the peritoneal cavity rather than relying solely on direct deep tissue invasion.

This dissemination pattern helps explain widespread serosal disease.

Schematic

Slide 29 · Ovarian carcinoma has a characteristic serosal pattern

Diffuse seeding of peritoneal serosal surfaces is described.

Implants are often small, about 0.1–0.5 cm description.

These nodules may be extensive despite limited invasion of underlying organ parenchyma.

Widespread

Often small nodules

Predominantly surface-based

Slide 30 · Peritoneal implants are not equivalent to deep organ invasion

Serosal seeding

Numerous tumor nodules coat peritoneal surfaces.

Parenchymal invasion

The text notes that these serosal implants only rarely penetrate deeply into underlying organ tissue.

Slide 31 · Ascites marks a major complication of dissemination

Peritoneal seeding

Diffuse surface disease

Ascites

Abdominal distention

When ovarian carcinoma spreads throughout the peritoneal cavity, ascites often develops.

Fluid accumulation can be massive and contribute substantially to abdominal enlargement.

Schematic

Slide 32 · Ascitic fluid can contain malignant exfoliated cells

Ascitic fluid containing exfoliated tumor cells.

This finding connects tumor biology with the possibility of cytologic evaluation.

No sensitivity, specificity, or negative-test exclusion rule for ascites cytology is given in the source.

Tumor exfoliation

Fluid-based cells

Interpretation requires context

Slide 33 · Regional lymph nodes may become involved

Ovarian carcinoma can spread to regional lymph nodes.

Nodal involvement represents a separate route from free intraperitoneal exfoliation.

The textbook does not provide a nodal distribution map or incidence percentage in this section.

Peritoneal route

Lymphatic involvement

Slide 34 · Distant metastatic sites extend beyond the pelvis

Liver

Metastatic involvement is described.

Lungs

An extraabdominal metastatic site reported in the source.

Gastrointestinal tract / others

Visceral metastases may occur in addition to peritoneal surface implants.

Slide 35 · Three dissemination patterns have different meanings

Peritoneal

Cells exfoliate and implant on serosal surfaces.

Nodal

Tumor reaches regional lymph nodes.

Distant

Metastases appear in the liver, lung, gastrointestinal tract, or elsewhere.

Slide 36 · Why is ovarian cancer frequently advanced at diagnosis?

Subtle / shared symptoms

Growing lesion

Peritoneal spread

Advanced presentation

Initial manifestations can be nonspecific.

The tumor may enlarge or seed peritoneal surfaces before detection.

Many patients therefore first present with advanced disease.

Schematic

Slide 37 · Extent of peritoneal disease is prognostically important

Serous tumor prognosis is related to both microscopic grade and distribution of peritoneal disease.

Spread outside the ovary changes the stage of disease.

Extent and grade should be interpreted independently rather than treated as interchangeable.

Histologic grade

Anatomic extent

Biologic tempo

Slide 38 · Grade influences clinical tempo after extraovarian spread

Lower-grade disease

Can progress slowly despite extension beyond the ovary; Survival may be prolonged.

Higher-grade disease

Frequently extensive at presentation and associated with rapid deterioration.

Slide 39 · Textbook-reported five-year outcomes differ by extent

Disease category

Confined to ovary

Peritoneal involvement

Borderline serous tumors

100%

Approximately 90%

Malignant serous tumors

70%

Approximately 25%

Rates reported for the specified serous tumor categories; Not patient-specific predictions.

Slide 40 · Five-year survival is not equivalent to cure

Borderline tumors can recur many years after original presentation.

A favorable five-year survival percentage therefore does not exclude delayed progression or recurrence.

Time horizon matters when interpreting outcomes in indolent ovarian tumors.

Delayed relapse

Long follow-up

Survival ≠ cure

Slide 41 · The diagnostic challenge is early-stage recognition

Most patients with ovarian carcinoma are diagnosed with advanced disease.

The source identifies late stage at presentation as the principal reason for poorer long-term survival relative to cervical or endometrial carcinoma.

Improved early-detection assays remain an important research goal.

Late presentation

Worse long-term outcomes

Need for early detection

Slide 42 · Screening tests require both sensitivity and specificity

Sensitivity

An early-detection test should identify a sufficiently high proportion of patients with disease.

Specificity

A screening test must also avoid excessive false positives among people without disease.

Slide 43 · No proposed blood antigen assay is adequate for screening

Tumor antigens and secreted tumor products have been investigated for early detection.

The proposed assays do not achieve the sensitivity and specificity needed for clinical utility as general early-detection tests.

This conclusion should not be confused with their separate roles in managing known disease.

Research biomarkers

Unmet performance standard

Distinct surveillance indication

Slide 44 · CA-125 has a defined role in known disease

Known ovarian cancer

CA-125 measurement

Serial clinical assessment

Recurrence / progression monitoring

Serum CA-125 is used to follow patients with diagnosed ovarian carcinoma.

Its stated role is monitoring recurrence or progression, not establishing population-wide screening efficacy.

Schematic

Slide 45 · Marker monitoring is not general-population screening

Known disease

A longitudinal marker can assist follow-up of a recognized malignancy.

No diagnosed disease

Robbins does not support CA-125 as a screening assay for asymptomatic populations.

Slide 46 · High-risk identification differs from cancer detection

Risk identification

Family history and hereditary variants identify individuals with increased susceptibility.

Tumor detection

A separate question: Whether current disease can be identified accurately before symptoms.

Slide 47 · Familial susceptibility is clinically consequential

Inherited BRCA1 or BRCA2 variants increase susceptibility to ovarian and breast cancer.

Strong family history is another signal for elevated inherited risk.

The source places risk identification before discussion of preventive surgery.

BRCA1 / BRCA2

Strong family history

Risk management

Slide 48 · BRCA-associated risk is substantial but heterogeneous

The textbook estimates lifetime ovarian cancer risk by age 70 of approximately 20%–60% for BRCA1/2 mutation carriers.

The broad estimate spans heterogeneous hereditary groups and is not an individual prediction.

Genetic susceptibility changes prevention discussions but does not establish that a tumor is present.

By age 70

20%–60% in source

Risk ≠ diagnosis

Slide 49 · Reproductive history modifies risk associations

Nulliparity / low parity

The source associates lower parity with increased frequency of serous ovarian carcinoma.

Oral contraceptives / tubal ligation

In women aged 40–59 years, prior oral contraceptive use or tubal ligation is associated with reduced ovarian cancer risk.

Slide 50 · The fallopian tube is a prevention-relevant site

Tubal epithelium

Possible STIC precursor

High-grade serous carcinoma

Risk-reduction target

High-grade serous carcinoma frequently originates in the distal fallopian tube.

Removing the tube may interrupt a potential anatomic source before invasive cancer emerges.

This rationale is not proof that every ovarian carcinoma is preventable by salpingectomy.

Schematic

Slide 51 · Risk-reducing salpingectomy targets tubal epithelium

The source describes salpingectomy as a developing approach for reducing serous ovarian carcinoma risk.

The mechanism-based rationale is removal of a frequently implicated site of origin.

Long-term preventive impact was not established discussion.

Anatomic prevention

Potential benefit

Outcome uncertainty

Slide 52 · Salpingo-oophorectomy is an established risk-reducing option

For individuals at hereditary or strong familial risk, risk-reducing salpingo-oophorectomy.

The strategy includes the fallopian tube as well as ovary, reflecting the tubal-origin evidence.

The textbook excerpt does not specify timing, patient selection thresholds, or surgical adverse effects.

High inherited risk

Tube + ovary

Individual decision context

Slide 53 · Prevention effectiveness still requires long follow-up

Rationale

Inherited risk and a tubal precursor pathway support risk-reducing interventions.

Evidence horizon

The textbook explicitly notes uncertainty about the long-term effect of preventive strategies in high-risk groups.

Slide 54 · Case: Pelvic symptoms without a specific histology

A patient has lower abdominal pain, gradual abdominal enlargement, urinary frequency, and pelvic pressure.

Discuss:

Which features suggest an adnexal process?

Why can symptoms alone not identify epithelial tumor subtype?

Slide 55 · Case: Ascites and diffuse serosal nodules

An ovarian carcinoma is accompanied by massive ascites and numerous small nodules coating peritoneal surfaces.

Discuss:

What route of spread explains the pattern?

Does diffuse serosal involvement require deep organ parenchymal invasion?

Slide 56 · Case: How should a CA-125 result be used?

A patient with an established ovarian carcinoma is being assessed for possible progression.

Discuss:

Which use of CA-125 is supported by the source?

Why does this not validate CA-125 screening in asymptomatic individuals?

Slide 57 · Case: Inherited risk and prevention

A person with a pathogenic BRCA variant asks why discussion of ovarian cancer prevention includes the fallopian tubes.

Discuss:

What precursor concept underlies the explanation?

Which two risk-reducing operations are described, and what uncertainty remains?

Slide 58 · Three clinical decisions should be kept separate

Course

Determine histology, grade, and distribution of disease.

Detection

Distinguish evaluation of symptoms from screening and monitoring known cancer.

Prevention

Identify hereditary risk and discuss risk reduction without overclaiming efficacy.

Slide 59 · References and source boundaries

Robbins, Cotran & Kumar. Pathologic Basis of Disease. 11th ed. (2026), Chapter 22, pp. 923–929.

Primary topic: Clinical Course, Detection, and Prevention of Ovarian Epithelial Tumors, pp. 928–929.

Parent context: ovarian epithelial tumor classification, serous and other subtypes, pp. 923–928.

No original chapter PDF or licensed textbook pathology plates were available for figure-level cross-checking.